April 25, 2018 9:44 AM ET

Pharmaceuticals

Company Overview of Alcobra Ltd.

Company Overview

As of November 15, 2017, Alcobra Ltd. was acquired by Arcturus Therapeutics, Inc., in a reverse merger transaction. Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of proprietary pharmaceutical products. The company’ s product candidates include Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy; and Metadoxine Extended Release (MDX), a proprietary oral drug for the treatment of ADHD and other cognitive disorders, including Fragile X syndrome. Alcobra Ltd. was f...

Azrieli Triangle Building

39th Floor

132 Derech Menachem Begin

Tel Aviv,  6701101

Israel

Founded in 2008

19 Employees

Phone:

972 72 220 4661

Key Executives for Alcobra Ltd.

Alcobra Ltd. does not have any Key Executives recorded.

Alcobra Ltd. Key Developments

Alcobra Ltd.(NasdaqGM:ARCT) dropped from NASDAQ Composite Index

Alcobra Ltd. has been removed from NASDAQ Composite Index .

Alcobra Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017

Alcobra Ltd. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company reported loss before taxes on income of $2,528,000 against $7,787,000 a year ago. Net loss attributable to holders of ordinary shares was $2,555,000 or $0.09 per share basic and diluted against $7,802,000 or $0.28 per share basic and diluted a year ago. Net cash used in operating activities was $1,334,000 against $6,675,000 a year ago. For the nine months, the company reported loss before taxes on income of $9,715,000 against $18,613,000 a year ago. Net loss attributable to holders of ordinary shares was $9,766,000 or $0.35 per share basic and diluted against $18,676,000 or $0.68 per share basic and diluted a year ago. Net cash used in operating activities was $10,334,000 against $15,218,000 a year ago. Purchase of property and equipment was $5,000 against $32,000 a year ago.

Alcobra Ltd. Announces Board Appointments

Alcobra Ltd., at its extraordinary general meeting of shareholders held on October 19, 2017, elected Mr. Yuval Yanai and Mr. Amir Efrati as director of the company.

Similar Private Companies By Industry

Company Name Region
Abital Pharma Pipelines Ltd. Middle East/Africa
Active PX Ltd. Middle East/Africa
Advanced Inhalation Technology Ltd. Middle East/Africa
Alvit LCS Pharma Ltd Middle East/Africa
Angio B Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 27, 2017
--
Merger/Acquisition
June 9, 2017
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alcobra Ltd., please visit www.alcobra-pharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.